Scarica l'app Stockscreener
69.97
0.11%
0.08
Dopo l'orario di chiusura:
69.87
-0.10
-0.14%
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché DXCM Giù?
Forum
Previsione
Frazionamento azionario
Precedente Chiudi:
$69.89
Aprire:
$70.57
Volume 24 ore:
3.66M
Relative Volume:
0.62
Capitalizzazione di mercato:
$27.29B
Reddito:
$4.52B
Utile/perdita netta:
$720.70M
Rapporto P/E:
38.94
EPS:
1.7968
Flusso di cassa netto:
$1.06B
1 W Prestazione:
-4.20%
1M Prestazione:
+0.11%
6M Prestazione:
-8.42%
1 anno Prestazione:
-20.78%
Intervallo 1D:
$68.68
$70.68
Intervallo di 1 settimana:
$68.68
$75.36
Portata 52W:
$54.11
$93.25
Dexcom Inc Stock (DXCM) Company Profile
Nome
Dexcom Inc
Settore
Industria
Telefono
(858) 200-0200
Indirizzo
6340 SEQUENCE DRIVE, SAN DIEGO, CA
Compare DXCM vs ABT, SYK, MDT, BSX, EW
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
DXCM
Dexcom Inc
|
69.97 | 27.26B | 4.52B | 720.70M | 1.06B | 1.7968 |
|
ABT
Abbott Laboratories
|
110.83 | 189.68B | 44.33B | 6.48B | 6.92B | 3.7033 |
|
SYK
Stryker Corp
|
358.29 | 138.60B | 25.12B | 3.25B | 4.28B | 8.4018 |
|
MDT
Medtronic Plc
|
102.90 | 131.98B | 34.76B | 4.79B | 5.21B | 3.7017 |
|
BSX
Boston Scientific Corp
|
76.27 | 115.14B | 20.08B | 2.89B | 3.82B | 1.9391 |
|
EW
Edwards Lifesciences Corp
|
78.71 | 45.32B | 5.88B | 1.34B | 799.60M | 2.3489 |
Dexcom Inc Stock (DXCM) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2026-01-12 | Downgrade | Barclays | Equal Weight → Underweight |
| 2025-12-02 | Aggiornamento | Morgan Stanley | Equal-Weight → Overweight |
| 2025-11-25 | Iniziato | Evercore ISI | In-line |
| 2025-10-21 | Ripresa | Stifel | Buy |
| 2025-09-08 | Downgrade | Oppenheimer | Outperform → Perform |
| 2025-08-21 | Iniziato | Argus | Buy |
| 2025-06-16 | Iniziato | Truist | Buy |
| 2025-05-30 | Iniziato | Goldman | Buy |
| 2025-04-10 | Iniziato | Mizuho | Outperform |
| 2025-02-03 | Aggiornamento | Redburn Atlantic | Neutral → Buy |
| 2025-01-16 | Aggiornamento | Robert W. Baird | Neutral → Outperform |
| 2024-07-26 | Downgrade | JP Morgan | Overweight → Neutral |
| 2024-07-26 | Downgrade | Robert W. Baird | Outperform → Neutral |
| 2024-05-30 | Iniziato | Redburn Atlantic | Neutral |
| 2024-03-12 | Iniziato | RBC Capital Mkts | Outperform |
| 2023-05-30 | Ripresa | Morgan Stanley | Equal-Weight |
| 2023-04-17 | Aggiornamento | Raymond James | Outperform → Strong Buy |
| 2023-03-29 | Iniziato | UBS | Buy |
| 2023-01-26 | Iniziato | Wolfe Research | Outperform |
| 2022-10-18 | Iniziato | Barclays | Equal Weight |
| 2022-10-12 | Iniziato | Jefferies | Buy |
| 2022-07-15 | Iniziato | Bernstein | Outperform |
| 2022-03-02 | Ripresa | BofA Securities | Buy |
| 2022-02-03 | Aggiornamento | BTIG Research | Neutral → Buy |
| 2022-01-19 | Aggiornamento | Wells Fargo | Equal Weight → Overweight |
| 2022-01-07 | Aggiornamento | Guggenheim | Neutral → Buy |
| 2021-10-18 | Downgrade | Guggenheim | Buy → Neutral |
| 2021-07-21 | Ripresa | Cowen | Outperform |
| 2021-05-28 | Aggiornamento | Wells Fargo | Underweight → Equal Weight |
| 2021-05-25 | Iniziato | Barclays | Overweight |
| 2021-04-15 | Iniziato | Atlantic Equities | Overweight |
| 2021-01-06 | Aggiornamento | UBS | Neutral → Buy |
| 2020-10-02 | Downgrade | Wells Fargo | Equal Weight → Underweight |
| 2020-05-27 | Reiterato | Piper Sandler | Overweight |
| 2020-05-14 | Iniziato | Wells Fargo | Equal Weight |
| 2020-03-05 | Iniziato | Citigroup | Buy |
| 2019-11-07 | Reiterato | Canaccord Genuity | Buy |
| 2019-11-07 | Aggiornamento | Guggenheim | Neutral → Buy |
| 2019-10-23 | Iniziato | Stifel | Buy |
| 2018-11-28 | Iniziato | UBS | Neutral |
| 2018-10-19 | Aggiornamento | Goldman | Sell → Neutral |
| 2018-09-12 | Aggiornamento | Northland Capital | Under Perform → Market Perform |
| 2018-08-02 | Reiterato | Canaccord Genuity | Buy |
| 2018-07-02 | Aggiornamento | Raymond James | Mkt Perform → Outperform |
| 2018-06-08 | Aggiornamento | JP Morgan | Neutral → Overweight |
| 2018-05-11 | Iniziato | BofA/Merrill | Buy |
| 2018-05-03 | Reiterato | Canaccord Genuity | Buy |
| 2018-04-04 | Iniziato | Goldman | Sell |
| 2018-04-04 | Iniziato | Guggenheim | Neutral |
| 2018-03-23 | Aggiornamento | Robert W. Baird | Neutral → Outperform |
| 2018-01-04 | Downgrade | Northland Capital | Market Perform → Under Perform |
| 2017-09-28 | Reiterato | Wedbush | Outperform |
Mostra tutto
Dexcom Inc Borsa (DXCM) Ultime notizie
DexCom Expands Stelo AI Tools As It Seeks Stickier CGM Users - simplywall.st
A Look Into DexCom Inc's Price Over Earnings - Benzinga
DexCom (DXCM) Reports Next Week: Wall Street Expects Earnings Growth - Finviz
DXCM Upgrades Stelo With AI-Powered Smart Meal Logging Features - TradingView
Growth Value: Should I average down on DexCom Inc stockWeekly Risk Report & Risk Adjusted Swing Trade Ideas - baoquankhu1.vn
DexCom’s CEO Believes Diabetics On GLP-1s Should Also Wear CGMs - MedCity News
Risks Report: Is DexCom Inc a strong growth stockJuly 2025 Retail & Daily Growth Stock Tips - baoquankhu1.vn
Dexcom adds enhanced smart meal logging feature to Stelo CGM - MassDevice
Stelo Adds Enhanced Smart Meal Logging Features as Dexcom Continues to Transform Personal Glucose Management - Eagle-Tribune
Continuous Glucose Monitoring Devices Market to Reach US$10.72 - openPR.com
New Dexcom CEO Takes on ‘Thrilling’ Task Leading CGM Giant - San Diego Business Journal
Continuous Glucose Monitoring Market to Grow at a Robust CAGR - openPR.com
Peterson Wealth Services Grows Stock Position in DexCom, Inc. $DXCM - MarketBeat
DexCom, Inc. (DXCM) Stock Analysis: Exploring a 16.64% Upside Potential in the Growing Medical Devices Sector - DirectorsTalk Interviews
DexCom Faces Split Analyst Views As Competition Pressures Core CGM Markets - Sahm
DexCom’s Q4 Beat And 2026 Targets Tested By Rising CGM Competition - Yahoo Finance
What DexCom (DXCM)'s Strong Q4 Beat and 2026 Margin Guidance Means For Shareholders - Yahoo Finance
DexCom, Inc. $DXCM Shares Purchased by Mirae Asset Global Investments Co. Ltd. - MarketBeat
Q4 Preliminary Figures and 2026 Guidance Make DexCom (DXCM) Look Attractive - Insider Monkey
Investigation into DexCom's Corporate Governance Breaches - Intellectia AI
HALPER SADEH LLC ENCOURAGES DEXCOM, INC. SHAREHOLDERS TO CONTACT THE FIRM TO DISCUSS THEIR RIGHTS - PR Newswire
Price Over Earnings Overview: DexCom - Sahm
DexCom, Inc. $DXCM Holdings Cut by J. Safra Sarasin Holding AG - MarketBeat
Here's Why DexCom (DXCM) is a Strong Momentum Stock - Yahoo Finance
Federated Hermes Inc. Trims Position in DexCom, Inc. $DXCM - MarketBeat
Is DexCom (DXCM) Pricing Reflect Longer Term Returns And Glucose Monitoring Growth Story - Yahoo Finance
Hussman Strategic Advisors Inc. Takes $2.83 Million Position in DexCom, Inc. $DXCM - MarketBeat
Y Intercept Hong Kong Ltd Purchases New Position in DexCom, Inc. $DXCM - MarketBeat
Barclays Downgrades Dexcom (DXCM) to Underweight Citing Intensifying Competition in Core Segments - Insider Monkey
Dexcom Schedules Fourth Quarter and Fiscal Year 2025 Earnings Release and Conference Call for February 12, 2026 at 4:30 p.m. Eastern Time. - Chartmill
INVESTOR NOTICE: Kaskela Law Firm Announces Stockholder Investigation of DexCom, Inc. (NASDAQ - marketscreener.com
Intact Investment Management Inc. Has $2.28 Million Stock Position in DexCom, Inc. $DXCM - MarketBeat
CIBC Asset Management Inc Has $10.51 Million Holdings in DexCom, Inc. $DXCM - MarketBeat
12 Best US Stocks to Buy and Hold in 2026 - Insider Monkey
Mitsubishi UFJ Trust & Banking Corp Sells 102,717 Shares of DexCom, Inc. $DXCM - MarketBeat
Strs Ohio Sells 14,796 Shares of DexCom, Inc. $DXCM - MarketBeat
DexCom, Inc. $DXCM Shares Purchased by Sector Gamma AS - MarketBeat
Rakuten Investment Management Inc. Buys New Position in DexCom, Inc. $DXCM - MarketBeat
Here's why you should hold DexCom stock in your portfolio for now - MSN
How Investors Are Reacting To DexCom (DXCM) Revenue Guidance After G7 Recall and CGM Expansion Plans - simplywall.st
Jennison Associates LLC Has $678.98 Million Stock Holdings in DexCom, Inc. $DXCM - MarketBeat
Teacher Retirement System of Texas Acquires 92,643 Shares of DexCom, Inc. $DXCM - MarketBeat
Baillie Gifford & Co. Sells 823,027 Shares of DexCom, Inc. $DXCM - MarketBeat
New DexCom CEO Remains Focused on Addressing Recent Quality Issues - morningstar.com
DexCom Inc (DXCM) Trading 4.47% Higher on Jan 22 - GuruFocus
Campbell & CO Investment Adviser LLC Has $629,000 Holdings in DexCom, Inc. $DXCM - MarketBeat
Allstate Corp Invests $964,000 in DexCom, Inc. $DXCM - MarketBeat
Dexcom Reports 22% Revenue Growth to $1.2 Billion in 2024 Amidst Challenges - Intellectia AI
1 Growth Stock Down 19% to Buy Right Now - Finviz
Analysts Offer Insights on Healthcare Companies: BillionToOne, Inc. Class A (BLLN) and Dexcom (DXCM) - The Globe and Mail
FDA Flags Serious Software Issue in Dexcom Glucose Monitoring App - Drugwatch.com
Dexcom Inc Azioni (DXCM) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
2.01%
2.02%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):